Global Neurodegenerative Drugs Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Neurodegenerative Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Neurodegenerative Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Neurodegenerative Drugs market include TEVA, Sanofi, Novartis, Luye Pharma, Livzon Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Pfizer and Huahai Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Neurodegenerative Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Neurodegenerative Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Neurodegenerative Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neurodegenerative Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neurodegenerative Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Neurodegenerative Drugs sales, projected growth trends, production technology, application and end-user industry.
Neurodegenerative Drugs Segment by Company
TEVA
Sanofi
Novartis
Luye Pharma
Livzon Pharmaceutical
Kanghong Pharmaceutical
Jingxin Pharmaceutical
Pfizer
Huahai Pharmaceutical
Hisun Pharmaceutical
Haisco Pharmaceutical
GlaxoSmithKline
Ark Pharmaceutical
Dongcheng Biochemicals
BORA PHARMACEUTICALS
UCB
Merck Serono
Boehringer Ingelheim
Biogen Idec
Neurodegenerative Drugs Segment by Type
NMDA
SSRIs
Dopamine Inhibitors
Neurodegenerative Drugs Segment by Application
Parkinson’s Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Alzheimer’s Disease
Neurodegenerative Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Neurodegenerative Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Neurodegenerative Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Neurodegenerative Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Neurodegenerative Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neurodegenerative Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurodegenerative Drugs industry.
Chapter 3: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Neurodegenerative Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Neurodegenerative Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Neurodegenerative Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Neurodegenerative Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Neurodegenerative Drugs market include TEVA, Sanofi, Novartis, Luye Pharma, Livzon Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Pfizer and Huahai Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Neurodegenerative Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Neurodegenerative Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Neurodegenerative Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neurodegenerative Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neurodegenerative Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Neurodegenerative Drugs sales, projected growth trends, production technology, application and end-user industry.
Neurodegenerative Drugs Segment by Company
TEVA
Sanofi
Novartis
Luye Pharma
Livzon Pharmaceutical
Kanghong Pharmaceutical
Jingxin Pharmaceutical
Pfizer
Huahai Pharmaceutical
Hisun Pharmaceutical
Haisco Pharmaceutical
GlaxoSmithKline
Ark Pharmaceutical
Dongcheng Biochemicals
BORA PHARMACEUTICALS
UCB
Merck Serono
Boehringer Ingelheim
Biogen Idec
Neurodegenerative Drugs Segment by Type
NMDA
SSRIs
Dopamine Inhibitors
Neurodegenerative Drugs Segment by Application
Parkinson’s Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Alzheimer’s Disease
Neurodegenerative Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Neurodegenerative Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Neurodegenerative Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Neurodegenerative Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Neurodegenerative Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neurodegenerative Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurodegenerative Drugs industry.
Chapter 3: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Neurodegenerative Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Neurodegenerative Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
209 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Neurodegenerative Drugs Sales Value (2020-2031)
- 1.2.2 Global Neurodegenerative Drugs Sales Volume (2020-2031)
- 1.2.3 Global Neurodegenerative Drugs Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Neurodegenerative Drugs Market Dynamics
- 2.1 Neurodegenerative Drugs Industry Trends
- 2.2 Neurodegenerative Drugs Industry Drivers
- 2.3 Neurodegenerative Drugs Industry Opportunities and Challenges
- 2.4 Neurodegenerative Drugs Industry Restraints
- 3 Neurodegenerative Drugs Market by Company
- 3.1 Global Neurodegenerative Drugs Company Revenue Ranking in 2024
- 3.2 Global Neurodegenerative Drugs Revenue by Company (2020-2025)
- 3.3 Global Neurodegenerative Drugs Sales Volume by Company (2020-2025)
- 3.4 Global Neurodegenerative Drugs Average Price by Company (2020-2025)
- 3.5 Global Neurodegenerative Drugs Company Ranking (2023-2025)
- 3.6 Global Neurodegenerative Drugs Company Manufacturing Base and Headquarters
- 3.7 Global Neurodegenerative Drugs Company Product Type and Application
- 3.8 Global Neurodegenerative Drugs Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Neurodegenerative Drugs Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Neurodegenerative Drugs Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Neurodegenerative Drugs Market by Type
- 4.1 Neurodegenerative Drugs Type Introduction
- 4.1.1 NMDA
- 4.1.2 SSRIs
- 4.1.3 Dopamine Inhibitors
- 4.2 Global Neurodegenerative Drugs Sales Volume by Type
- 4.2.1 Global Neurodegenerative Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Neurodegenerative Drugs Sales Volume by Type (2020-2031)
- 4.2.3 Global Neurodegenerative Drugs Sales Volume Share by Type (2020-2031)
- 4.3 Global Neurodegenerative Drugs Sales Value by Type
- 4.3.1 Global Neurodegenerative Drugs Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Neurodegenerative Drugs Sales Value by Type (2020-2031)
- 4.3.3 Global Neurodegenerative Drugs Sales Value Share by Type (2020-2031)
- 5 Neurodegenerative Drugs Market by Application
- 5.1 Neurodegenerative Drugs Application Introduction
- 5.1.1 Parkinson’s Disease
- 5.1.2 Amyotrophic Lateral Sclerosis
- 5.1.3 Huntington Disease
- 5.1.4 Alzheimer’s Disease
- 5.2 Global Neurodegenerative Drugs Sales Volume by Application
- 5.2.1 Global Neurodegenerative Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Neurodegenerative Drugs Sales Volume by Application (2020-2031)
- 5.2.3 Global Neurodegenerative Drugs Sales Volume Share by Application (2020-2031)
- 5.3 Global Neurodegenerative Drugs Sales Value by Application
- 5.3.1 Global Neurodegenerative Drugs Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Neurodegenerative Drugs Sales Value by Application (2020-2031)
- 5.3.3 Global Neurodegenerative Drugs Sales Value Share by Application (2020-2031)
- 6 Neurodegenerative Drugs Regional Sales and Value Analysis
- 6.1 Global Neurodegenerative Drugs Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Neurodegenerative Drugs Sales by Region (2020-2031)
- 6.2.1 Global Neurodegenerative Drugs Sales by Region: 2020-2025
- 6.2.2 Global Neurodegenerative Drugs Sales by Region (2026-2031)
- 6.3 Global Neurodegenerative Drugs Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Neurodegenerative Drugs Sales Value by Region (2020-2031)
- 6.4.1 Global Neurodegenerative Drugs Sales Value by Region: 2020-2025
- 6.4.2 Global Neurodegenerative Drugs Sales Value by Region (2026-2031)
- 6.5 Global Neurodegenerative Drugs Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Neurodegenerative Drugs Sales Value (2020-2031)
- 6.6.2 North America Neurodegenerative Drugs Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Neurodegenerative Drugs Sales Value (2020-2031)
- 6.7.2 Europe Neurodegenerative Drugs Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Neurodegenerative Drugs Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Neurodegenerative Drugs Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Neurodegenerative Drugs Sales Value (2020-2031)
- 6.9.2 South America Neurodegenerative Drugs Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Neurodegenerative Drugs Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Neurodegenerative Drugs Sales Value Share by Country, 2024 VS 2031
- 7 Neurodegenerative Drugs Country-level Sales and Value Analysis
- 7.1 Global Neurodegenerative Drugs Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Neurodegenerative Drugs Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Neurodegenerative Drugs Sales by Country (2020-2031)
- 7.3.1 Global Neurodegenerative Drugs Sales by Country (2020-2025)
- 7.3.2 Global Neurodegenerative Drugs Sales by Country (2026-2031)
- 7.4 Global Neurodegenerative Drugs Sales Value by Country (2020-2031)
- 7.4.1 Global Neurodegenerative Drugs Sales Value by Country (2020-2025)
- 7.4.2 Global Neurodegenerative Drugs Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.9.2 France Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.16.2 China Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.19.2 India Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Neurodegenerative Drugs Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Neurodegenerative Drugs Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Neurodegenerative Drugs Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 TEVA
- 8.1.1 TEVA Comapny Information
- 8.1.2 TEVA Business Overview
- 8.1.3 TEVA Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.1.4 TEVA Neurodegenerative Drugs Product Portfolio
- 8.1.5 TEVA Recent Developments
- 8.2 Sanofi
- 8.2.1 Sanofi Comapny Information
- 8.2.2 Sanofi Business Overview
- 8.2.3 Sanofi Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Sanofi Neurodegenerative Drugs Product Portfolio
- 8.2.5 Sanofi Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Comapny Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Novartis Neurodegenerative Drugs Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Luye Pharma
- 8.4.1 Luye Pharma Comapny Information
- 8.4.2 Luye Pharma Business Overview
- 8.4.3 Luye Pharma Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Luye Pharma Neurodegenerative Drugs Product Portfolio
- 8.4.5 Luye Pharma Recent Developments
- 8.5 Livzon Pharmaceutical
- 8.5.1 Livzon Pharmaceutical Comapny Information
- 8.5.2 Livzon Pharmaceutical Business Overview
- 8.5.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 8.5.5 Livzon Pharmaceutical Recent Developments
- 8.6 Kanghong Pharmaceutical
- 8.6.1 Kanghong Pharmaceutical Comapny Information
- 8.6.2 Kanghong Pharmaceutical Business Overview
- 8.6.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 8.6.5 Kanghong Pharmaceutical Recent Developments
- 8.7 Jingxin Pharmaceutical
- 8.7.1 Jingxin Pharmaceutical Comapny Information
- 8.7.2 Jingxin Pharmaceutical Business Overview
- 8.7.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 8.7.5 Jingxin Pharmaceutical Recent Developments
- 8.8 Pfizer
- 8.8.1 Pfizer Comapny Information
- 8.8.2 Pfizer Business Overview
- 8.8.3 Pfizer Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Pfizer Neurodegenerative Drugs Product Portfolio
- 8.8.5 Pfizer Recent Developments
- 8.9 Huahai Pharmaceutical
- 8.9.1 Huahai Pharmaceutical Comapny Information
- 8.9.2 Huahai Pharmaceutical Business Overview
- 8.9.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 8.9.5 Huahai Pharmaceutical Recent Developments
- 8.10 Hisun Pharmaceutical
- 8.10.1 Hisun Pharmaceutical Comapny Information
- 8.10.2 Hisun Pharmaceutical Business Overview
- 8.10.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 8.10.5 Hisun Pharmaceutical Recent Developments
- 8.11 Haisco Pharmaceutical
- 8.11.1 Haisco Pharmaceutical Comapny Information
- 8.11.2 Haisco Pharmaceutical Business Overview
- 8.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 8.11.5 Haisco Pharmaceutical Recent Developments
- 8.12 GlaxoSmithKline
- 8.12.1 GlaxoSmithKline Comapny Information
- 8.12.2 GlaxoSmithKline Business Overview
- 8.12.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.12.4 GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
- 8.12.5 GlaxoSmithKline Recent Developments
- 8.13 Ark Pharmaceutical
- 8.13.1 Ark Pharmaceutical Comapny Information
- 8.13.2 Ark Pharmaceutical Business Overview
- 8.13.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 8.13.5 Ark Pharmaceutical Recent Developments
- 8.14 Dongcheng Biochemicals
- 8.14.1 Dongcheng Biochemicals Comapny Information
- 8.14.2 Dongcheng Biochemicals Business Overview
- 8.14.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.14.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
- 8.14.5 Dongcheng Biochemicals Recent Developments
- 8.15 BORA PHARMACEUTICALS
- 8.15.1 BORA PHARMACEUTICALS Comapny Information
- 8.15.2 BORA PHARMACEUTICALS Business Overview
- 8.15.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.15.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
- 8.15.5 BORA PHARMACEUTICALS Recent Developments
- 8.16 UCB
- 8.16.1 UCB Comapny Information
- 8.16.2 UCB Business Overview
- 8.16.3 UCB Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.16.4 UCB Neurodegenerative Drugs Product Portfolio
- 8.16.5 UCB Recent Developments
- 8.17 Merck Serono
- 8.17.1 Merck Serono Comapny Information
- 8.17.2 Merck Serono Business Overview
- 8.17.3 Merck Serono Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.17.4 Merck Serono Neurodegenerative Drugs Product Portfolio
- 8.17.5 Merck Serono Recent Developments
- 8.18 Boehringer Ingelheim
- 8.18.1 Boehringer Ingelheim Comapny Information
- 8.18.2 Boehringer Ingelheim Business Overview
- 8.18.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.18.4 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
- 8.18.5 Boehringer Ingelheim Recent Developments
- 8.19 Biogen Idec
- 8.19.1 Biogen Idec Comapny Information
- 8.19.2 Biogen Idec Business Overview
- 8.19.3 Biogen Idec Neurodegenerative Drugs Sales, Value and Gross Margin (2020-2025)
- 8.19.4 Biogen Idec Neurodegenerative Drugs Product Portfolio
- 8.19.5 Biogen Idec Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Neurodegenerative Drugs Value Chain Analysis
- 9.1.1 Neurodegenerative Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Neurodegenerative Drugs Sales Mode & Process
- 9.2 Neurodegenerative Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Neurodegenerative Drugs Distributors
- 9.2.3 Neurodegenerative Drugs Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



